Lv3
218 积分 2023-06-29 加入
Neoadjuvant PD-1 and PD-L1 Blockade With Chemotherapy for Borderline Resectable and Unresectable Stage III Non–Small Cell Lung Cancer
18天前
已完结
Real-World Safety and Efficacy of Consolidation Durvalumab After Chemoradiation Therapy for Stage III Non-small Cell Lung Cancer: A Systematic Review and Meta-analysis
24天前
已完结
Real‐world effectiveness and safety of treatment strategies for unresectable, driver‐negative Stage III NSCLC : A retrospective multicentre study
1个月前
已完结
Management of Stage III Non-Small-Cell Lung Cancer: ASCO Guideline
4个月前
已完结
Subsequent treatment for locally advanced non-small-cell lung cancer that progressed after definitive chemoradiotherapy and consolidation therapy with durvalumab: a multicenter retrospective analysis (TOPGAN 2021-02)
6个月前
已完结
Baseline PD-L1 expression and tumour-infiltrated lymphocyte status predict the efficacy of durvalumab consolidation therapy after chemoradiotherapy in unresectable locally advanced patients with non-small-cell lung cancer
6个月前
已完结
Dosimetric predictors of pneumonitis in locally advanced non-small cell lung cancer patients treated with chemoradiation followed by durvalumab
6个月前
已完结
Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations
6个月前
已完结
Locally Advanced Lung Cancer
7个月前
已完结
Cost-effectiveness and Budgetary Consequence Analysis of Durvalumab Consolidation Therapy vs No Consolidation Therapy After Chemoradiotherapy in Stage III Non–Small Cell Lung Cancer in the Context of the US Health Care System
7个月前
已完结
皖公网安备34019202002308
